Time to legalize psychedelics? Campus debate weighs therapeutic need vs. safety questions

Psychedelic legalization debates weigh faster therapeutic access against the need for rigorous safety research. The Harvard Gazette reports on a Petrie-Flom Center event, “Toward Psychedelics Access: Go Faster or Slower?”, moderated by David Plotz and featuring experts who disagree on pace but share concerns about evidence quality and risk. David Yaden highlights that even defining “psychedelics” is contested and argues that clinical effects cannot be easily generalized across substances like psilocybin, ketamine, and MDMA, pointing to limited research funding as a key barrier. Matthew Buckley emphasizes urgent healing needs for veterans and first responders based on experiences involving ibogaine and 5-MeO-DMT, while Holly Fernandez Lynch stresses that medical claims should meet the same proof standards as other medicines. Cat Packer argues for oversight and regulation, warning that commercialization can move too quickly or be shaped by bad incentives, as seen in examples from cannabis retail.